Next 10 |
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM Topline data to be presented Saturday, June 1, 2024 at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago N...
2024-05-23 00:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-14 07:08:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual S&P 500 ...
2024-05-03 18:03:42 ET Summary NovoCure's Q1 earnings exceeded expectations, with growing revenue and cost reductions. Market data suggests faster growth for specialty oncology treatments, providing tailwinds for NovoCure's business. The core business is strong, with accelerat...
2024-05-03 01:00:11 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2024 Earnings Call Transcript
2024-05-02 11:43:08 ET NovoCure Limited (NVCR) Q1 2024 Earnings Conference Call May 02, 2024 08:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief F...
2024-05-02 07:51:28 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $13...
2024-05-02 07:07:02 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure Q1 2024 Earnings Preview Novocure climbs ...
Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 milli...
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR...
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM Topline data to be presented Saturday, June 1, 2024 at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago N...
2024-05-23 00:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Monday. Shares of Overseas Shipholding Group, Inc. (NYSE:OSG) rose ...